Hims & Hers Health (NYSE:HIMS) experienced a 40% increase in share price last quarter, possibly fueled by strong financial performance and future growth projections. The company announced earnings on ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...

Q4 2024 showed more blockbuster growth for Hims & Hers. Revenue growth accelerated to 95% year over year, hitting $481 ...

Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective hoisted by Leerink Partners from $24.00 to $40.00 in a report published on Tuesday,Benzinga reports. They currently have a market ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

Alphabet, Hims & Hers Health, and UnitedHealth Group are the three Healthcare stocks to watch today, according to MarketBeat’s stock screener tool. Healthcare stocks are shares in companies that ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money ...

Stock in Hims & Hers Health was bound to tumble once it could no longer sell compounded versions of the weight-loss drug Wegovy at scale. But with lofty expectations about its remaining anti-obesity ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...